• The co crystal structure of GPR

  2022-02-18

  

  The co-crystal structure of GPR40 complexed with TAK-875 provided precise structural information for the rational design of novel GPR40 agonists. The key interactions between the carboxylate with the residues Arg183, Arg258, Tyr91 and Tyr240 of GPR40 were observed. And Trp174ECL2 was oriented nearly

• A769662 The inhibitory activities of the

  2022-02-18

  

  The inhibitory activities of the compounds with the modification of the amino group against human liver FBPase are summarized in . Replacement of the amino group of with hydrophobic substituent such as a methyl group () led to a substantial loss of activity (IC=995nM). Similarly, replacement with ha

• br Introduction Migraine is a chronic neurological disorder

  2022-02-18

  

  Introduction Migraine is a chronic neurological disorder characterized by recurrent episodes of headache. It affects more than 10% of the population worldwide, resulting in a staggering amount of episodic disability, a substantial decrease in the quality of life and a concomitant loss in producti

• The H R antagonist JNJ

  2022-02-18

  

  The H3R antagonist JNJ-17216498, developed by Johnson & Johnson, has entered clinical trial studies, but no information regarding its structure has been publicized to date. A phase II study of JNJ-17216498 monotherapy has been completed for patients with narcolepsy, but the results are not publicall

• Pharmacologic approaches of inhibiting GSNOR

  2022-02-17

  

  Pharmacologic approaches of inhibiting GSNOR activity have reached the point of clinical development with the recent announcement of the first cystic fibrosis patients treated with the first-in-class GSNOR inhibitor, N6022 (N30 Pharmaceuticals). Clinical development is ongoing for other indications

• Our study has strengths and limitations

  2022-02-17

  

  Our study has strengths and limitations. We believe we are the 1st to report a novel model of secondary hypogonadism. Several animal models for hypogonadotropic hypogonadism (kisspeptin and the kisspeptin receptor knockout) exist but we are unaware of animal models of secondary hypogonadism with dif

• To facilitate the development of novel diagnostic and therap

  2022-02-17

  

  To facilitate the development of novel diagnostic and therapeutic interventions in NASH, a plethora of animal models have been used to identify molecular targets that are involved in the onset and progression of NASH. In view of recent advances in the understanding of the pathogenesis of NASH and pr

• br Results and discussion br Conclusions br Introduction The

  2022-02-17

  

  Results and discussion Conclusions Introduction There is no effective treatment for HIV-associated neurocognitive disorder (HAND) which affects about half of the over 36 million people infected (Saylor et al., 2016). HIV can remain in the AP26113 during combination antiretroviral therapy (

• We found that most antigenic regions in GlyT C are

  2022-02-17

  

  We found that most antigenic regions in GlyT1C are located in the second half of the GlyT1C-terminus, which is in concert with previously published results (Olivares et al., 1994). We however further show that in contrast to epitopes 554–625 which are affected by calcium only minimally, the epitopes

• When testing the novel DA CH peptide

  2022-02-17

  

  When testing the novel DA-CH3 peptide, it was found that it is superior to liraglutide in the MPTP mouse model of PD at a dose of 25 nmol/kg ip once-daily for 7 days. In the Rotarod and grip strength assessment, DA-CH3 was superior to liraglutide in reversing the MPTP–induced motor impairment. Dopam

• THZ531 In order to test whether the enhanced hyperpolarizati

  2022-02-17

  

  In order to test whether the enhanced hyperpolarization in the presence of increasing amounts of extracellular Ca2+ could be due to an ionophore effect of NS309, red cell uptake of 45Ca and partition of 45Ca into a water/n-octanol phase +/−100 μM NS309 were determined. However, no indication of iono

• Bafetinib The first GSM was identified from

  2022-02-17

  

  The first GSM was identified from the discovery of non-steroidal anti-inflammatory drugs (NSAIDs). An amyloid reducing GSM that also suppresses inflammation is desirable. Inflammatory response is an invariable characteristic of AD pathogenesis, in part triggered by Aβ. During AD onset and progressio

• br Conclusions br Acknowledgments This study

  2022-02-17

  

  Conclusions Acknowledgments This study was supported by funds from the National Natural Science Foundation of China (NSFC 31360245, 31460258) and the Applied Basic Research Foundation of Yunnan Province of China (2011FZ111). Introduction Acute myocardial infarction is the undoubted cause o

• Due to the presence of all FGFRs in

  2022-02-16

  

  Due to the presence of all FGFRs in the epithelium, there are several FGFs ligands that could be binding to these FGF receptors, namely FGFs 1–4, 8–10, 16 and 18–20. By evaluating the known roles of FGFs in epithelial-mesenchymal interactions and in bone development, this list can be reduced. For ex

• br Declaration of interest br Acknowledgments br This work

  2022-02-16

  

  Declaration of interest Acknowledgments This work was supported by grants from the Polish National Science Centre (PRELUDIUM grant no. 2013/11/N/NZ5/00270) and the European Commission FP7 Project Beta-JUDO (grant number 279 153), European Union EIT Health project DeTecT2D, Swedish Diabetes A

16799 records 527/1120 page Previous Next First page 上5页 526527528529530 下5页 Last page